Skip to main content
. Author manuscript; available in PMC: 2023 Sep 5.
Published in final edited form as: J Thorac Oncol. 2022 Mar 21;17(6):779–792. doi: 10.1016/j.jtho.2022.02.011

Figure 3. TP53 alterations, mutation load, chromosomal instability and mutagenesis.

Figure 3.

A. Tumor mutational burden (TMB) in TP53 wild type (WT) vs altered (MT) tumors (Wilcoxon p-value=0.00051). B. Proportion copy number altered (CNA) in TP53 WT vs MT (Wilcoxon p-value=0.0014). C. TMB in TP53 WT vs MT tumors stratified by treatment context (TP53 WT, pre vs post-treatment, p-value=0.042; TP53 MT, pre vs post-treatment, p-value=5.228e-05; pre-treatment, TP53 MT vs WT, p=0.02239; post-treatment, TP53 MT vs WT, p=0.01113). D. CNA load in TP53 WT vs MT tumors stratified by treatment context (TP53 WT, pre vs post-treatment, p-value=0.11; TP53 MT, pre vs post-treatment, p-value=0.45; pre-treatment, TP53 MT vs WT, p-value=0.00126). E. Proportion of mutations attributable to each signature in TP53 MT vs WT (Signature 4, p=0.0012; Signature 5, p=0.0282). F. Proportion of mutations attributable to each signature in pre vs post-treatment samples, TP53 WT samples (Signature 1, p=0.020. G. Proportion of mutations attributable each signature in pre vs post-treatment samples, TP53 MT samples; Signature 1, p=0.0024). All other comparisons, p > 0.05. *p<0.05; **p<0.01, ***p<0.001. N=311 samples, 212 with TP53 alterations, 99 without.